Perseus Proteomics Inc.
Records under this name other than the patents Perseus Proteomics Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 11 patents it holds.
Back to Perseus Proteomics Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,546,537 | Streptavidin Having Low Immunogenicity and Use Thereof Formerly held In force · High confidence | In force | High confidence | |
| US 8,815,211 | Radioactive metal-labeled anti-cadherin antibody Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 10,227,407 | Anti-Podoplanin Antibody Formerly held In force · High confidence | In force | High confidence | |
| US 7,691,586 | A Method for Predicting and Judging the Recurrence of Liver Cancer After Treating Liver Cancer Term ended Term ended Apr 5, 2026 · High confidence | Term ended | Term ended Apr 5, 2026 | High confidence |
| US 9,273,140 | Antibody for detecting DNA damage in cells utilizing cell membrane surface antigen Ly6D Lapsed on the fee record Ended Mar 1, 2024 · From the USPTO record | Lapsed on the fee record | Ended Mar 1, 2024 | From the USPTO record |
| US 9,513,292 | Method for diagnosing cancer by detecting GPC3 Term ended Term ended Oct 18, 2023 · From the USPTO record | Term ended | Term ended Oct 18, 2023 | From the USPTO record |
| US 7,875,705 | Tumor Diagnostic Agent Used in Pet Comprising ANTI-ROBO1 Antibody Lapsed on the fee record Ended Jan 25, 2023 · High confidence | Lapsed on the fee record | Ended Jan 25, 2023 | High confidence |
| US 8,455,249 | Highly Effective Anti-Cadherin Antibody for Induction of Antibody-Dependent Cellular Cytotoxicity in Vivo Lapsed on the fee record Ended Jun 4, 2021 · High confidence | Lapsed on the fee record | Ended Jun 4, 2021 | High confidence |
| US 9,644,029 | Cancer Diagnosis and Treatment of Cancer Using Anti-Robo 1 Antibody Lapsed on the fee record Ended May 9, 2021 · High confidence | Lapsed on the fee record | Ended May 9, 2021 | High confidence |
| US 8,398,981 | Therapeutic agents for alzheimer's disease and cancer Lapsed on the fee record Ended Mar 19, 2021 · From the USPTO record | Lapsed on the fee record | Ended Mar 19, 2021 | From the USPTO record |